Bausch + Lomb (BLCO) Stock Price, News & Analysis

Company Overview

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, pharmaceuticals and surgical applications. Its portfolio is intended to address a broad range of eye conditions and support patients, eye-care professionals and surgical specialists.

The company’s vision-care products include contact lenses and contact-lens-care solutions, while its pharmaceutical portfolio includes prescription and over-the-counter treatments for conditions affecting the eyes. Bausch + Lomb also supplies ophthalmic surgical products, equipment and technologies used in procedures such as cataract and refractive surgery.

Founded in 1853 in Rochester, New York, Bausch + Lomb operates internationally and sells its products in numerous markets around the world. The company was formerly part of Bausch Health Companies and became an independent publicly traded company in 2022. Its chief executive officer is Brent Saunders.

Key Stats

• Today's Range: $16.30 to $16.77
• 50-Day Range: $15.83 to $18.16
• 52-Week Range: $14.44 to $18.92
• Volume: 4,901 shs
• Average Volume: 434,562 shs
• Market Capitalization: $5.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.46
• Consensus Rating: Hold

Bausch + Lomb Stock Analysis - MarketRank™

Bausch + Lomb scored higher than 90% of companies evaluated by MarketBeat, and ranked 39th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Bausch + Lomb has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 1 strong buy rating, 6 buy ratings, 7 hold ratings, and 1 sell rating.

Upside Potential

Bausch + Lomb has a consensus price target of $19.46, representing about 18.5% upside from its current price of $16.42.

Amount of Analyst Coverage

Bausch + Lomb has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 28.40%

Earnings Growth

Earnings for Bausch + Lomb are expected to grow by 28.40% in the coming year, from $0.81 to $1.04 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch + Lomb is -34.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch + Lomb is -34.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Bausch + Lomb has a PEG Ratio of 0.52. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Bausch + Lomb has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.84% of the float of Bausch + Lomb has been sold short.

Short Interest Ratio / Days to Cover

Bausch + Lomb has a short interest ratio ("days to cover") of 9.84.

Change versus previous month

Short interest in Bausch + Lomb has recently decreased by 6.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bausch + Lomb does not currently pay a dividend.

Dividend Growth

Bausch + Lomb does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.32

News Sentiment

Bausch + Lomb has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Bausch + Lomb this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bausch + Lomb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,194,370.00 in company stock.

Percentage Held by Insiders

1.45% of the stock of Bausch + Lomb is held by insiders.

Percentage Held by Institutions

11.07% of the stock of Bausch + Lomb is held by institutions.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/19/2026
• Next Earnings (Confirmed): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NYSE:BLCO
• CIK: 1860742
• Web: www.bausch.com
• Phone: (908) 541-5456
• Fax: N/A
• Employees: 13,000
• Year Founded: 1853

Price Target and Rating

• Average Price Target for Bausch + Lomb: $19.46
• High Price Target: $24.00
• Low Price Target: $16.00
• Potential Upside/Downside: +18.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.47
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 20.27
• P/E Growth: 0.52
• Net Income: -$360 million
• Net Margins: -3.21%
• Pretax Margin: -1.22%
• Return on Equity: 4.14%
• Return on Assets: 1.93%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 1.55
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: $5.10 billion
• Price / Sales: 1.15
• Cash Flow: $1.66 per share
• Price / Cash Flow: 9.88
• Book Value: $18.40 per share
• Price / Book: 0.89

Miscellaneous

• Outstanding Shares: 357,390,000
• Free Float: 352,203,000
• Market Cap: $5.87 billion
• Optionable: Optionable
• Beta: 0.56